Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Members of the International Hearing Society (IHS) are gearing up to celebrate World Hearing Day on March 3, 2025, to raise awareness of hearing healthcare and address the stigma attached to hearing ...

CoinW, a global leader in cryptocurrency exchanges, made a strong impression at Consensus HK 2025 as an official 4 Block ...

Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.

That's encouraging, considering that Vertex's current top-selling CF drug Trikafta/Kaftrio raked in revenue of $10.2 billion last year. Adding to the excitement, the FDA approved Vertex's acute pain ...

Strong demand for its CF therapy, Trikafta/Kaftrio, delivered $10.2 billion in revenue for the year. We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...